Participants were randomly assigned to receive a dermal patch containing a high concentration of capsaicin (640 µg/cm 2 [8%]) or a low concentration of capsaicin (3.2 µg/cm 2 [0.04%]), which was ...

In the study, participants were treated with the capsaicin patch showed 33 per cent reduction in pain compared to four per cent of those who were given a placebo.

In July 2020, Grünenthal’s US subsidiary Averitas Pharma received US FDA approval for a QUTENZA (capsaicin) 8% patch for treating neuropathic pain associated with Diabetic Peripheral Neuropathy ...